MedPath

ASTELLAS PHARMA

🇯🇵Japan
Ownership
-
Established
2005-01-01
Employees
-
Market Cap
$22.5B
Website
https://www.astellas.com/

A Comparison Study Between Protopic (Tacrolimus) Ointment and Elidel (Pimecrolimus) Cream in Treating Subjects With Atopic Dermatitis

Phase 4
Completed
Conditions
Dermatitis, Atopic
Interventions
First Posted Date
2008-04-24
Last Posted Date
2014-09-18
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
413
Registration Number
NCT00666302

Trial of Two Dosing Regimens of Micafungin Versus Caspofungin for the Treatment of Esophageal Candidiasis

Phase 3
Completed
Conditions
Candidiasis, Oral
Interventions
First Posted Date
2008-04-24
Last Posted Date
2014-08-20
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
454
Registration Number
NCT00665639
Locations
🇧🇷

7 Sites, Sao Paulo, Brazil

🇧🇷

3 Sites, Belo Horizonte, Brazil

🇦🇷

5 Sites, Buenos Aires, Argentina

and more 2 locations

A Study to Assess Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder

Phase 3
Completed
Conditions
Urinary Bladder, Overactive
Interventions
Drug: Placebo
Drug: Mirabegron
First Posted Date
2008-04-21
Last Posted Date
2024-11-20
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
2149
Registration Number
NCT00662909

A Placebo-controlled Study With an Extension Examining the Safety and Efficacy of Alefacept in Psoriatic Arthritis

Phase 2
Completed
Conditions
Psoriatic Arthritis
Interventions
First Posted Date
2008-04-16
Last Posted Date
2014-09-18
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
185
Registration Number
NCT00659412

Assess the Efficacy and Safety of Alefacept With Narrow Band Ultraviolet B Phototherapy (nbUVB) vs. Alefacept Alone in Chronic Plaque Psoriasis Subjects

Phase 4
Completed
Conditions
Plaque Psoriasis
Interventions
Procedure: Narrow Band UVB Phototherapy
Drug: alefacept
First Posted Date
2008-04-15
Last Posted Date
2013-01-08
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
98
Registration Number
NCT00658606

A Study of Pharmacokinetics and Safety of Alefacept in Caucasian and Japanese Healthy Volunteers

Phase 1
Completed
Conditions
Pharmacokinetics of Alefacept
Interventions
Drug: alefacept
Drug: placebo
First Posted Date
2008-04-07
Last Posted Date
2013-02-28
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
75
Registration Number
NCT00653822

Zolpidem (Myslee) Post Marketing Study in Adolescent Patients With Insomnia - Evaluation With Polysomnography

Phase 4
Completed
Conditions
Insomnia
Sleep Initiation and Maintenance Disorders
Interventions
First Posted Date
2008-04-07
Last Posted Date
2017-02-17
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
11
Registration Number
NCT00653562

A Study to Compare Early Steroid Withdrawal and Long-Term Steroid Maintenance Therapy in Kidney Transplant Patients

Phase 4
Completed
Conditions
Renal Transplantation
Interventions
Drug: tacrolimus
Drug: CellCept
Drug: steroids (methylprednisone or prednisone)
First Posted Date
2008-04-01
Last Posted Date
2011-11-17
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
397
Registration Number
NCT00650468

Tacrolimus (FK506) P-III, Open-label Study in Refractory Ulcerative Colitis Patients

Phase 3
Completed
Conditions
Ulcerative Colitis
Interventions
First Posted Date
2008-03-26
Last Posted Date
2014-08-26
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
32
Registration Number
NCT00643071

Tacrolimus as Secondary Intervention vs. Continuation of Cyclosporine in Renal Transplant Patients With Chronic Renal Allograft Failure (CRAF)

Phase 4
Completed
Conditions
Renal Transplantation
Chronic Renal Allograft Failure
Interventions
First Posted Date
2008-03-17
Last Posted Date
2017-02-16
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
107
Registration Number
NCT00637143
© Copyright 2025. All Rights Reserved by MedPath